Helen Barold, MD
Clinical Cardiac Electrophysiology · Rockville, MDNPI 1114005238
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $80,577 of the $83,149 with a category attached, or 96.9%. Medtronic accounts for 97.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $81,429 and has fallen 99.1% since, to $704 in 2025. Among clinical cardiac electrophysiology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $989.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$81K
- Novo Nordisk$389
- Amgen$241
- Boehringer Ingelheim$224
- Novartis$197
- Pfizer$153
- plus $605 from 15 others
What the payments were for
- Royalty or licence$80,57797%
- Travel & lodging$6751%
- Food & beverage$1,8962%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 6 | $81,340 |
| Novo Nordisk | 10 | $389 |
| Amgen | 11 | $241 |
| Boehringer Ingelheim | 11 | $224 |
| Novartis | 10 | $197 |
| Pfizer | 8 | $153 |
| Baxter Healthcare | 3 | $107 |
| Boston Scientific | 3 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Johnson & Johnson | 3 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $59 |
| Lilly USA, LLC | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $34 |
| Philips North America LLC | 2 | $34 |
| GSK | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Itamar Medical Inc | 1 | $18 |
| Merck | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$83,149 in reported general payments places this provider in the 90th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
See all clinical cardiac electrophysiology providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 352 | $411,924 |
| EntrestoSacubitril/Valsartan | 64 | $79,623 |
| OzempicSemaglutide | 38 | $54,117 |
| XareltoRivaroxaban | 34 | $47,855 |
| JardianceEmpagliflozin | 31 | $31,482 |
| WegovySemaglutide | 15 | $21,511 |
| Propafenone Hcl ErPropafenone Hcl | 24 | $14,862 |
| FarxigaDapagliflozin Propanediol | 18 | $12,859 |
| MounjaroTirzepatide | 12 | $10,159 |
| Rosuvastatin Calcium | 295 | $5,882 |
| Metoprolol Succinate | 341 | $5,839 |
| Ezetimibe | 73 | $2,640 |
| Losartan Potassium | 200 | $2,479 |
| Atorvastatin Calcium | 203 | $2,347 |
| Amlodipine Besylate | 180 | $2,044 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $153 | $411,924352 claims |
| NovartisEntresto | $197 | $79,62364 claims |
| Novo NordiskOzempic, Wegovy | $389 | $75,62753 claims |
| Johnson & JohnsonXarelto | $60 | $47,85534 claims |
| Boehringer IngelheimJardiance | $224 | $31,48231 claims |
| Lilly USA, LLCMounjaro | $43 | $10,15912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
Other clinical cardiac electrophysiology in Rockville
- Sean BeinartRockville$315K
- Alexander AsserRockville$20K
- Tushina JainRockville$11K
- Charles LoveBaltimore$238K
- Hugh CalkinsBaltimore$202K
- Paresh ShahBaltimore$97K
- Jonathan ChrispinBaltimore$77K
- Sung LeeTakoma Park$68K
- Stephen ShorofskyBaltimore$63K
- Nilofar IslamTowson$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.